(S)-5-methyl-5-azaspiro[2.4]heptane-6-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-5-methyl-5-azaspiro[2.4]heptane-6-carboxylic acid
• 英文别名: (S)-5-Methyl-5-azaspiro[2.4]heptane-6-carboxylic acid；(6S)-5-methyl-5-azaspiro[2.4]heptane-6-carboxylic acid
• 化学式: C₈H₁₃NO₂
• 分子量: 155.197
• InChiKey: XZAVSDIZYROBLG-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-5-methyl-5-azaspiro[2.4]heptane-6-carboxylic acid 在 lithium aluminium tetrahydride 、 palladium on activated charcoal 、 methanesulfonato(2-dicyclohexylphosphino-2’,6’-di-i-propoxy-1,1’-biphenyl)(2’-methylamino-1,1‘-biphenyl-2-yl)palladium(II) 、 氢气 、 caesium carbonate 作用下， 以 四氢呋喃 、 异丙醇 、 甲苯 为溶剂， 反应 3.5h， 生成 (S)-2-(cyanomethyl)-4-{2-[((S)-5-methyl-5-azaspiro[2.4]heptan-6-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl}piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Kras-G12C抑制剂杂环化合物

  摘要：

  本申请涉及一类式I所示Kras‑G12C抑制剂杂环化合物，及其制备方法和该类化合物在肿瘤疾病，如肺癌、结直肠癌和胰腺癌等中的预防和治疗用途。在制备过程中，通过SN2反应、上保护、偶联反应、脱保户、缩合反应等一系列反应，得到通式化合物I。

  公开号：

  CN113004269A

文献信息

• [EN] SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION<br/>[FR] INHIBITEURS SPIRO BICYCLIQUES DE L'INTERACTION MÉNINE-MLL
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018050686A1

  公开（公告）日：2018-03-22

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplasia syndrome (MDS) and diabetes.

  本发明涉及对哺乳动物具有治疗和/或预防作用的药物制剂，特别是螺环双环化合物、包含此类化合物的药物组合物及其作为menin/MLL蛋白/蛋白相互作用抑制剂的用途，适用于治疗癌症、骨髓增生异常综合征（MDS）和糖尿病等疾病。
• Ether Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239920A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了有关制备抑制补体因子D的化合物、使用方法和制备过程，所述化合物包括具有式I的化合物，或其药用可接受的盐或组合物，其中A组上的R12或R13是醚（R32）。本文描述的抑制剂靶向因子D并在替代性补体途径的早期和关键点上抑制或调节补体级联，并减少因子D调节经典和凝集素补体途径的能力。本文描述的因子D抑制剂能够减少过度激活的补体，这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。
• PROCESSES FOR THE PREPARATION OF 5-AZASPIRO[2.4]HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20140187793A1

  公开（公告）日：2014-07-03

  The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (Ia), (Ib) and (Ic):

  本发明涉及一种改进的制备5-azaspiro[2.4]庚烷-6-羧酸及其衍生物的过程，这些化合物是合成生物活性分子的有用中间体，特别是在合成肝炎C病毒NS5A抑制剂方面。具体而言，本发明涉及制备式（Ia），（Ib）和（Ic）化合物的过程和中间体：
• PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20140316143A1

  公开（公告）日：2014-10-23

  The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):

  本发明涉及制备新型苯并咪唑衍生物的方法和中间体，尤其是在合成丙型肝炎病毒NS5A抑制剂方面。特别是，本发明涉及制备式（I-a）化合物的方法和中间体：
• Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239838A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了包括公式I或其药学上可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备方法。本文所描述的抑制剂靶向因子D并在替代补体途径的早期和关键点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少补体过度激活，该过度激活已与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。